Metyrapone in Cushing’s syndrome: a profile of its use

Metyrapone (Metopirone®), a pyridine derivative, is useful treatment option for the management of patients with endogenous Cushing’s syndrome, based on evidence from more than six decades its use in clinical practice, prospective and retrospective studies, as well case reports. associated rapid onset action effective reducing cortisol levels improving and/or biochemical features cortisol-related comorbidities syndrome. The efficacy metyrapone was demonstrated all aetiologies condition, when used range settings (including presurgery combination other drugs) short long term. generally tolerated gastrointestinal adverse events being most commonly reported. Endogenous syndrome rare disease, resulting hypersecretion, substantial morbidity mortality. Surgery mainstay majority syndrome; however, medical therapy increasingly used, particularly surgery not indicated or unsuccessful, while waiting radiotherapy to be effective. Oral approved EU. Evidence has been studies. (≈ 2 h), reduces levels, improves demonstrates sustained term; evident settings. Given tolerability profile,